The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density

[1]  S. Ferrari,et al.  Author contributions , 2021 .

[2]  Kylie L. Gorringe,et al.  The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density , 2020, npj Breast Cancer.

[3]  M. Yaffe,et al.  Predictors of mammographic density among women with a strong family history of breast cancer , 2019, BMC Cancer.

[4]  Kylie L. Gorringe,et al.  Molecular comparison of interval and screen‐detected breast cancers , 2019, The Journal of pathology.

[5]  D. Rhodes,et al.  Molecular breast imaging detected invasive lobular carcinoma in dense breasts: A case report , 2019, Clinical case reports.

[6]  C. Nickson,et al.  Prospective Validation of the NCI Breast Cancer Risk Assessment Tool and the Autodensity Mammographic Density Tool on 40,000 Australian Screening Program Participants , 2018, Journal of Global Oncology.

[7]  I. Campbell,et al.  Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility , 2018, Genetics in Medicine.

[8]  Kylie L. Gorringe,et al.  Mutations in RECQL are not associated with breast cancer risk in an Australian population , 2018, Nature Genetics.

[9]  E. Thompson,et al.  High mammographic density in women is associated with protumor inflammation , 2018, Breast Cancer Research.

[10]  P. Mukherjee,et al.  An overview of mammographic density and its association with breast cancer , 2018, Breast Cancer.

[11]  Michael T. Zimmermann,et al.  Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas , 2018, Cell reports.

[12]  E. Thompson,et al.  Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs , 2018, Breast Cancer Research.

[13]  N. Rosenfeld,et al.  Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma , 2016, The journal of pathology. Clinical research.

[14]  A. Whittemore,et al.  Case-control study of mammographic density and breast cancer risk using processed digital mammograms , 2016, Breast Cancer Research.

[15]  N. Rosenfeld,et al.  The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes , 2016, Nature Communications.

[16]  N. Schultz,et al.  Deletions linked to TP53 loss drive cancer through p53-independent mechanisms , 2016, Nature.

[17]  R. Gelber,et al.  Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Nicolai J. Birkbak,et al.  Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs , 2015, Biomarker Research.

[19]  A. Theocharis,et al.  Insights into the key roles of proteoglycans in breast cancer biology and translational medicine. , 2015, Biochimica et biophysica acta.

[20]  B. Keller,et al.  Associations between breast density and a panel of single nucleotide polymorphisms linked to breast cancer risk: a cohort study with digital mammography , 2015, BMC Cancer.

[21]  C. Vachon,et al.  Mammographic density and breast cancer risk by family history in women of white and Asian ancestry , 2015, Cancer Causes & Control.

[22]  Jos Jonkers,et al.  CopywriteR: DNA copy number detection from off-target sequence data , 2015, Genome Biology.

[23]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Heang-Ping Chan,et al.  Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk , 2022 .

[25]  Bin Zhang,et al.  Association between mammographic features and clinicopathological characteristics in invasive ductal carcinoma of breast cancer. , 2014, Molecular and clinical oncology.

[26]  Chris Sander,et al.  Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.

[27]  C. Nickson,et al.  AutoDensity: an automated method to measure mammographic breast density that predicts breast cancer risk and screening outcomes , 2013, Breast Cancer Research.

[28]  Jiri Bartek,et al.  Replication stress links structural and numerical cancer chromosomal instability , 2013, Nature.

[29]  C. Nickson,et al.  AutoDensity: an automated method to measure mammographic breast density that predicts breast cancer risk and screening outcomes , 2013, Breast Cancer Research.

[30]  A. Vincent-Salomon,et al.  Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. , 2012, Cancer research.

[31]  G. Mills,et al.  Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer , 2012, British Journal of Cancer.

[32]  E. Ziv,et al.  CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues. , 2012, Cancer discovery.

[33]  Qifeng Yang,et al.  Mammographic features are associated with clinicopathological characteristics in invasive breast cancer. , 2011, Anticancer research.

[34]  Karla Kerlikowske,et al.  Volume of Mammographic Density and Risk of Breast Cancer , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[35]  Peter Kraft,et al.  Common variants in ZNF365 are associated with both mammographic density and breast cancer risk , 2011, Nature Genetics.

[36]  Mitchell H. Gail,et al.  Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer , 2010, Breast Cancer Research and Treatment.

[37]  Martin J. Yaffe,et al.  Family History, Mammographic Density, and Risk of Breast Cancer , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[38]  Anne M Kavanagh,et al.  Tumour Size at Detection According to Different Measures of Mammographic Breast Density , 2009, Journal of medical screening.

[39]  Anne M Kavanagh,et al.  Using Mammographic Density to Improve Breast Cancer Screening Outcomes , 2008, Cancer Epidemiology Biomarkers & Prevention.

[40]  F. Schmidt.  Meta-Analysis , 2008 .

[41]  V. McCormack,et al.  Breast Density and Parenchymal Patterns as Markers of Breast Cancer Risk: A Meta-analysis , 2006, Cancer Epidemiology Biomarkers & Prevention.

[42]  Russell Davies,et al.  Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. , 2006, Cancer research.

[43]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Norman Boyd,et al.  The Association of Measured Breast Tissue Characteristics with Mammographic Density and Other Risk Factors for Breast Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[45]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[46]  Peter H Watson,et al.  Mammographic density is related to stroma and stromal proteoglycan expression , 2003, Breast Cancer Research.

[47]  David Tritchler,et al.  Heritability of mammographic density, a risk factor for breast cancer. , 2002, The New England journal of medicine.

[48]  D. C. Henckel,et al.  Case report. , 1995, Journal.